Physician
Docs Medical INC
Docs Medical INC was paid $33.56M by Medicaid between Apr 2018 and Dec 2024, across 80 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 21% of everything it billed.
33Billing provider infoDOCS MEDICAL INC
EAST HAVEN, CT 06513
EAST HAVEN, CT 06513
33aNPI1104362169assigned 01/16/2017
33bProvider typeInternal Medicine Physician
28Total paid$33.56M
24GClaims793,916
24DCodes billed80
24AFirst – last monthApr 2018 – Dec 2024
Compared with peers
Next to other Internal Medicine Physician providers in Connecticut
Rank by total paid#4 of 295
Median peer was paid$35K
This provider vs. median954×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 7,438 | $860K | |
| 2019 | 19,806 | $2.20M | |
| 2020 | 174,956 | $7.96M | |
| 2021 | 224,403 | $9.32M | |
| 2022 | 121,531 | $5.80M | |
| 2023 | 118,536 | $3.75M | |
| 2024incomplete | 127,246 | $3.66M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 21% | 137,473 | 119,960 | $7.15M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 17% | 74,926 | 67,794 | $5.69M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 11% | 42,909 | 37,632 | $3.70M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 10% | 76,564 | 70,498 | $3.43M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 10% | 29,966 | 27,330 | $3.40M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 6.8% | 16,311 | 14,764 | $2.27M |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | 5.7% | 10,884 | 1,688 | $1.93M |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 4.5% | 54,433 | 47,808 | $1.50M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 4.1% | 44,277 | 39,969 | $1.37M |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 2.7% | 16,886 | 15,936 | $901K |
| 87428 | 1.1% | 14,750 | 13,095 | $358K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 11,376 | 10,055 | $292K |
68 more codes
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 12,837 | $272K |
| 96127 | <1% | 16,164 | $267K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 1,509 | $258K |
| 99051 | <1% | 22,142 | $140K | |
| 99442 | <1% | 2,710 | $102K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 485 | $55K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,261 | $52K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,613 | $47K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,640 | $46K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 557 | $45K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,242 | $36K |
| 99384 | <1% | 239 | $29K | |
| 99173 | <1% | 4,578 | $29K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 437 | $23K |
| 87631 | <1% | 208 | $21K | |
| 99385 | <1% | 154 | $20K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,898 | $16K |
| 94060 | <1% | 413 | $9K | |
| 94660 | <1% | 463 | $9K | |
| 94729 | <1% | 436 | $9K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 68 | $8K |
| 94727 | <1% | 429 | $7K | |
| 93000 | <1% | 489 | $7K | |
| 87430 | <1% | 481 | $5K | |
| 86580 | <1% | 795 | $5K | |
| 99386 | <1% | 28 | $4K | |
| 94726 | <1% | 210 | $4K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 33 | $4K |
| 99383 | <1% | 29 | $4K | |
| 94010 | <1% | 242 | $3K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 23 | $3K |
| 90686 | <1% | 362 | $2K | |
| 81025 | <1% | 433 | $2K | |
| 95115 | <1% | 288 | $2K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 119 | $2K |
| 80305 | <1% | 237 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 170 | $1K |
| 86618 | <1% | 107 | $1K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 15,092 | $1K |
| 85014 | <1% | 460 | $892.93 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 35 | $723.69 |
| 90715 | <1% | 30 | $706.44 | |
| 99454 | <1% | 162 | $590.06 | |
| 95117 | <1% | 53 | $472.70 | |
| 99457 | <1% | 87 | $301.00 | |
| G0454 | Physician documentation of face-to-face visit for durable medical equipment determination performed by nurse practitioner, physician assistant or clinical nurse specialist | <1% | 847 | $246.49 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 29 | $225.18 |
| 99441 | <1% | 102 | $207.38 | |
| 94375 | <1% | 380 | $186.30 | |
| 86308 | <1% | 18 | $83.98 | |
| 82962 | <1% | 32 | $69.44 | |
| 99458 | <1% | 13 | $52.34 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 48 | $27.65 |
| 99072 | <1% | 44,597 | $27.50 | |
| 3078F | <1% | 34,143 | $25.00 | |
| 3074F | <1% | 42,211 | $25.00 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 16 | $23.55 |
| 81002 | <1% | 14,189 | $23.05 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12 | $8.01 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 134 | $3.42 |
| 3077F | 0% | 1,233 | $0.00 | |
| G0444 | Annual depression screening, 5 to 15 minutes | 0% | 13 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 26 | $0.00 |
| 3075F | 0% | 3,759 | $0.00 | |
| 99000 | 0% | 681 | $0.00 | |
| 3079F | 0% | 12,765 | $0.00 | |
| M1008 | <50% of total number of a patient's outpatient ra encounters assessed | 0% | 17 | $0.00 |
| 3080F | 0% | 1,448 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCHARRON, LORNA (DIRECTOR HUMAN RESOURCES)